|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] The German drug market should grow at a rate of 3.19% between 2007-2012, with OTC drugs and the expansion of the generic sector being the main drivers of growth. Consumer health products should reach a value of US$8.5bn by 2012, due to increasing competition and the emergence of the internet as a major sales channel. The European Commission (EC) is currently challenging restrictive pharmacy ownership laws in a number of countries, with companies like Germany's Schlecker keenly awaiting the outcome. The retailer, which sells non-medicinal consumer health products in Germany, has recently opened an online pharmacy in the Netherlands, offering over 600 OTC products. Presently, Germany only allows selfemployed pharmacists to run pharmacies, preventing chains from entering the market. However, Schlecker is looking to circumvent this by running a mail order operation through its Dutch store. Elsewhere, plans to create a new drug approvals body in Germany have collapsed after the coalition parties in the government failed to agree on a framework for the agency, exemplifying how political infighting can de-rail reform initiatives. The new institution, provisionally called DAMA, would have replaced the current Federal Institute for Drugs and Medical Devices (BfArM), increasing the efficiency of the approvals process, which is beset by delays. Meanwhile, Germany takes 2nd place in BMI's revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Germany's position derives mainly from its strong country indicators with impressive scores in areas such as policy continuity and lack of corruption. The ratings also favour larger markets, which gives Germany a further advantage, due to its high per-capita expenditure on pharmaceuticals. However, sluggish growth is having a negative impact and BMI does not envisage Germany closing the gap on regional leader Switzerland over the forecast period. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummaryGermany Pharmaceuticals & Healthcare Industry SWOT Germany Political SWOT Germany Economic SWOT Chapter 2 - Germany: Business Environment RankingTable: Western Europe Business Environment Rankings Economics - Long Term risk Politics - Long Term risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Germany: Market SummaryChapter 4 - Regulatory RegimeIntellectual Property Developments Pricing & Reimbursement Issues Retail Industry Chapter 5 - Industry DevelopmentsHealthcare Sector Pharmaceutical Sector Domestic Industry Krankenkassen Foreign Industry R&D Sector Generics Sector Wholesaler Sector Offshoring Sector Epidemiology Biotech Sector Chapter 6 - Industry Forecast ScenarioOverall Market Forecast Table: German Drug Market Expenditure Forecasts 2005-2010 Key Growth Factors - Industry Table: German Health Expenditure Forecast Indicators 2004-2010 Key Growth Factors - Macroeconomic Table: Germany - Macroeconomic Forecasts Prescription Market Forecast Table: Germany Prescription Drugs Market Forecast Indicators OTC Market Forecast Table: German OTC Market Forecast Indicators 2005-2010 Generics and Branded Market Forecasts Table: German Generics and Branded Market Forecast Indicators 2005-2010 Export/Import Forecasts Table: German Pharmaceuticals Exports & Imports Forecasts 2005-2010 Key Risks to BMI's Forecast Scenario Chapter 7 - Country Snapshot: Germany Demographic DataSection 1: Population: Table: Demographic Indicators (2005) Table: Rural/Urban Breakdown Section 2: Education & Healthcare Table: Education Table: Healthcare: Vital Statistics Table: Healthcare: Expenditure Section 3: Labour Market And Spending Power Table: Employment Indicators Table: Consumption and Stratification Table: Wages per year Chapter 8 - Competitive Landscape54Overview Chapter 9 - Company ProfilesGlaxoSmithKline Pfizer Novartis Sanofi-Aventis Merck & Co Bayer Boehringer Ingelheim Chapter 10 - BMI Forecast ModellingHow we generate our industry forecasts Technical Process Pharmaceutical Industry Chapter 11 - Sources
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of European Pharmaceutical & Healthcare Sources[TOP] BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||